# Albumin-bound Paclitaxel (II)-Combined Regimens for Pancreatic Cancer

Source: https://onco.cc/trials/nct07828756/  
OnCo record `nct07828756` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cisplatin, nab-paclitaxel, capecitabine and gemcitabine in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.

## Summary

Albumin-bound Paclitaxel (II)-Combined Regimens for Pancreatic Cancer is a phase 2, interventional study registered as NCT07828756 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 147 participants, started 2026-09-30 and due to reach its primary completion in 2027-10-31. Interventions recorded: Cisplatin; Albumin-bound Paclitaxel (II); Albumin-bound Paclitaxel (II); Capecitabine; Capecitabine; Gemcitabine; Gemcitabine. Conditions listed: Pancreatic Cancer. Primary outcome: Progression-Free Survival (PFS); 1-Year Event-Free Survival Rate (1y-EFS Rate); Recommended Phase 2 Dose (RP2D). Pancreatic eligibility wording from the registry: "* Histopathologically confirmed pancreatic adenocarcinoma meeting any one of the following conditions: (1) Unresectable locally advanced or metastatic pancreatic cancer, with no prior systemic anti-tumor therapy for advanced disease". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07828756
- Phase: 2
- Setting: A Multi-cohort Exploratory Study to Evaluate the Efficacy and Safety of Albumin-bound Paclitaxel (II)-Combined Regimens for Pancreatic Cancer
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 147

## Sources

- ClinicalTrials.gov NCT07828756: https://clinicaltrials.gov/study/NCT07828756

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07828756.json